Risk-Adjusted Case Series
Also known as: risk-stratified case series, adjusted case series, risk-corrected case series
A risk-adjusted case series is an observational study design that reports outcomes for a consecutive or defined group of patients undergoing the same procedure or sharing a condition, while statistically correcting for differences in patient-level baseline risk. Rather than presenting raw complication or mortality rates, it compares observed outcomes against expected rates derived from a validated scoring model (e.g., POSSUM, APACHE, ASA grade), enabling fairer evaluation of clinical performance across institutions or over time.
Key highlights
- Accounts for case-mix variation, enabling fairer performance comparison across centres, surgeons, or time periods than raw rate reporting.
- Applicable to routinely collected clinical data without requiring a randomised control group.
- Transparent benchmarking framework: the O/E ratio and its confidence interval are interpretable by clinicians and audit committees.
- Supports quality improvement cycles by identifying unexpectedly high or low outcome rates that warrant further investigation.
- Compatible with national registry infrastructure and surgical audit programmes (e.g., UK SCTS, STS database).
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use a risk-adjusted case series when you have a single-centre or single-team dataset of consecutive patients and want to benchmark outcomes against expected rates given patient severity — particularly in surgical audit, quality improvement, or procedure safety reporting. It is appropriate when a randomised trial or comparative control group is unavailable or unethical, and when a validated risk model exists for the outcome of interest. Do NOT use it as a substitute for a controlled study when estimating treatment effects: the absence of a concurrent control group means causal conclusions cannot be drawn. Avoid it when the available risk model was calibrated in a very different patient population, as miscalibration will render the O/E ratio misleading. It is also unsuitable as a primary efficacy design for regulatory submissions.
Strengths & limitations
- Accounts for case-mix variation, enabling fairer performance comparison across centres, surgeons, or time periods than raw rate reporting.
- Applicable to routinely collected clinical data without requiring a randomised control group.
- Transparent benchmarking framework: the O/E ratio and its confidence interval are interpretable by clinicians and audit committees.
- Supports quality improvement cycles by identifying unexpectedly high or low outcome rates that warrant further investigation.
- Compatible with national registry infrastructure and surgical audit programmes (e.g., UK SCTS, STS database).
- No concurrent control group: causal inference about treatments or interventions is not possible.
- Results depend entirely on the validity and calibration of the chosen risk model; a poorly calibrated model produces misleading O/E ratios.
- Residual confounding from unmeasured or poorly measured patient characteristics cannot be eliminated.
- Retrospective data collection is common, introducing potential for incomplete or inconsistent covariate ascertainment.
- Small series have wide confidence intervals around O/E, making it difficult to detect true departures from expected performance.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
How is a risk-adjusted case series different from a standard case series?
A standard case series simply reports how many patients experienced a given outcome. A risk-adjusted case series goes further by applying a validated risk model to estimate how many outcomes were expected given the baseline severity of the specific patients treated, then expressing performance as an O/E ratio. This makes the results meaningful for benchmarking and quality assessment in a way that raw rates cannot.
Which risk model should I choose?
Choose the model validated for your clinical domain and outcome: POSSUM or P-POSSUM for general surgery morbidity and mortality, APACHE II/III for ICU mortality, EuroSCORE II for cardiac surgery, CHADS2-VASc for atrial fibrillation stroke risk, and so on. The model must have been calibrated in a population similar to yours, and ideally you should verify calibration in your own dataset using a Hosmer-Lemeshow test or calibration curve.
Can I use this design to show that my intervention works?
No. A risk-adjusted case series cannot establish causality because there is no control group. A favourable O/E ratio means outcomes were better than predicted for patients of that risk profile — it does not prove the intervention caused the improvement. Confounding by unmeasured factors remains. For efficacy evidence, a randomised controlled trial or, at minimum, a controlled observational study with propensity-score adjustment is needed.
How many patients do I need?
There is no universal minimum, but small series (fewer than 50 events) will produce O/E confidence intervals too wide to support meaningful conclusions. A common rule of thumb in regression modelling is at least 10 events per predictor variable in the risk model; for audit reporting, series large enough to generate stable O/E ratios — typically several hundred cases per reporting period — are preferred.
What is a funnel plot and why is it used here?
A funnel plot displays O/E ratios (or standardised mortality ratios) on the y-axis against the expected number of events on the x-axis, with control limits derived from a Poisson distribution. Units with small expected counts will have wider limits; large-volume units have narrower limits. Points outside the limits are statistical outliers warranting investigation. This approach, formalised by Spiegelhalter (2005), corrects for the tendency to over-interpret variation in small series.
Sources
- 1.Copeland, G. P., Jones, D., & Walters, M. (1991). POSSUM: a scoring system for surgical audit. British Journal of Surgery, 78(3), 355–360.
- 2.Mayer, E. K., Bottle, A., Darzi, A. W., & Aylin, P. (2004). Case volume and outcome in the surgical treatment of colorectal cancer. British Journal of Surgery, 91(9), 1104–1110.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). Risk-adjusted case series. ScholarGate. https://scholargate.app/epidemiology/risk-adjusted-case-series